Bristol Myers Squibb And Cellares Announced A Worldwide Capacity Reservation And Supply Agreement For The Manufacture Of CAR T Cell Therapies In A Transaction Valued Up To $380M In Upfront And Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb (BMY) and Cellares have entered into a worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies, valued up to $380M in upfront and milestone payments. Cellares will optimize and automate select BMY CAR T cell therapies on its Cell Shuttle platform, dedicating multiple systems for BMY's exclusive use in Smart Factories across the U.S., EU, and Japan.
April 22, 2024 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's agreement with Cellares for CAR T cell therapy manufacturing could significantly enhance its production capabilities and efficiency, potentially accelerating the delivery of therapies to market.
The partnership with Cellares allows BMY to leverage advanced manufacturing technologies, which could improve the scalability and speed of CAR T cell therapy production. This is likely to positively impact BMY's ability to meet demand and potentially enhance its competitive position in the biotech and healthcare market.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90